Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Study of Avelumab in Multiple Relapsed/Refractory Testicular Germ Cell Cancer

Next Previous
X
Search
Trial Profile

Phase II Study of Avelumab in Multiple Relapsed/Refractory Testicular Germ Cell Cancer

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 05 Nov 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Avelumab (Primary)
  • Indications Germ cell cancer; Seminoma; Testicular cancer
  • Focus Proof of concept; Therapeutic Use

    • Most Recent Events

    • 04 Jun 2019 Primary endpoint (To determine the efficacy (as measured by 12-week progression-free survival) of AVELUMAB in patients with multiple relapsed/refractory germ cell tumors (GCTs).) has not been met as per results presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
    • 04 Jun 2019 Results assessing efficacy of avelumab in testicular germ cell cancer patients, presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
    • 01 Jun 2019 Results published in the Investigational New Drugs

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top